Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data

Strand, Vibeke; Shah, Ruchitbhai; Atzinger, Chris; Zhou, Jifang; Clewell, Jerry; Ganguli, Arijit; Tundia, Namita

doi:10.1080/03007995.2019.1658974

Cited by 8 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SF-36 PCS and MCS scores, which are also commonly reported measures of HRQOL in clinical trials, were used as a proxy to estimate medical cost savings in the current study. In an adjusted analysis of administrative claims analysis, patients with RA who did not respond to targeted immunomodulator therapy had significantly higher all-cause and RA-related hospital admissions, outpatient visits, and prescription fills than patients who responded to therapy [ 41 ]. This increase in healthcare resource use was associated with significantly higher all-cause and RA-related medical costs (approximately 1.3-fold increase for each) in patients who did not respond to therapy compared with those who did respond, and patients who experience stiffness and/or fatigue use more healthcare resources and have higher medical costs than those who do not have these symptoms [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

The economic burden of rheumatoid arthritis (RA) to both patients and society is high.Healthcare costs are not often collected as outcomes in clinical trials of RA treatments.Patient-reported outcomes, such as the Short Form 36 (SF-36) Health Survey, are frequently collected in clinical trials to assess health-related quality of life from the patient perspective and may provide a means to evaluate the economic benefit of various RA treatments.What was learned from the study?On the basis of improvements in healthrelated quality of life in the short and long term, combination therapy with upadacitinib 15 mg once daily was associated with significantly lower direct medical costs than combination therapy with tofacitinib 5 mg twice daily in patients with moderate to severe RA.In addition, upadacitinib 15 mg once daily monotherapy was associated with significantly lower direct medical costs than methotrexate monotherapy for patients with moderate to severe RA.Estimates of healthcare expenditures using the patient-reported outcome SF-36 may improve our understanding of the economic implications of different RA treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…From this study cohort of patients newly diagnosed with IBD, cases (patients with IBD with fatigue) were identified using ICD-9/10 diagnosis codes for fatigue (780.7, R53.81, R53.82, and R53.83). 11 To be included, patients had to have a diagnosis of fatigue after the IBD index date, with no evidence of a fatigue diagnosis within the previous 12 months. The control group consisted of patients with IBD without a diagnosis of fatigue between their IBD index date to the end of follow-up.…”

Section: Methodsmentioning

confidence: 99%

Economic Burden of Fatigue in Inflammatory Bowel Disease

Ananthakrishnan

Desai

Lee

et al. 2023

Crohn's &Amp; Colitis 360

View full text Add to dashboard Cite

Background This retrospective study gathered medical/pharmacy claims data on patients with IBD between 01/01/2000 and 03/31/2019 from the IBM® MarketScan® commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with inflammatory bowel disease (IBD). Methods Eligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims) and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs was compared between cases and controls. Results Matched IBD cohorts (21,321 cases/21,321 controls) were identified (42% CD and 58% UC) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P<0.001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P<0.001); as well as significantly higher all-cause total direct healthcare costs (mean: $24,620 vs $15,324; P<0.001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups. Conclusions Presence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.

show abstract

“…Investigation of longitudinal data from the Early RA Network (ERAN) and Early RA Study (ERAS) in the United Kingdom for secular trends in disease trajectories for patients diagnosed in 1990, 2002, or 2010 have shown that while the initial 5-year course for inflammatory disease activity has improved over the decades, improvements in fatigue in early RA have been much smaller in magnitude and not statistically significant [13,14]. In a recent large administrative claims study, patients with diagnostic codes for RA and fatigue had higher all-cause and RA-specific health care utilization and costs compared to matched controls without fatigue, underscoring not only the burden of fatigue for patients but also for health care systems [15].…”

Section: Introductionmentioning

confidence: 99%

Multimorbidity and Fatigue in Rheumatoid Arthritis: A Cross-Sectional Study of a Population-Based Cohort

et al. 2020

View full text Add to dashboard Cite

Introduction: The objective was to evaluate the relationships between multimorbidity and overall fatigue as well as fatigue subdomains in patients with rheumatoid arthritis (RA). Methods: A cross-sectional study of a population-based cohort of patients with RA was performed. Fatigue was assessed using the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ). Patients' medical records were reviewed for 25 chronic comorbidities prior to the BRAF-MDQ. Linear and logistic regression models were used to estimate the differences in BRAF-MDQ total and subdomain (physical, living, cognitive, and emotional) scores associated with multimorbidity, adjusting for age, sex, disease duration, obesity, smoking, C-reactive protein, and RA autoantibodies. Higher BRAF-MDQ scores indicate greater fatigue severity. Results: The cohort included 192 patients, median age 62 years, and median RA duration 13 years. Multimorbidity was common with 93 (48%) having C 2 comorbidities, and 27 (14%) having C 4 comorbidities. The median BRAF-MDQ total score was 9 (interquartile range 3-18), with higher scores indicating greater fatigue. Patients with C 4 comorbidities had higher total BRAF-MDQ scores (median 16.5, interquartile range: 6.8-24.8) than patients with \ 4 comorbidities (7.5, 2.8-16.0; p = 0.014). Each additional comorbidity was associated with a 2.33 (95% confidence interval [CI] 1.10-3.56) unit increase in total BRAF-MDQ score (p \ 0.001), and the presence of C 4 comorbidities was associated with a 9.33 (95% CI 3.92-14.7) unit increase in total BRAF-MDQ score. Multimorbidity was significantly associated with all four fatigue subdomains in adjusted models. Conclusions: Multimorbidity is associated with increased fatigue in patients with RA. The findings suggest that interventions targeting multimorbidity could help alleviate treatmentrefractory fatigue in patients with RA and other rheumatic diseases.

show abstract

Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data

Cited by 8 publications

References 29 publications

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis

Economic Burden of Fatigue in Inflammatory Bowel Disease

Multimorbidity and Fatigue in Rheumatoid Arthritis: A Cross-Sectional Study of a Population-Based Cohort

Contact Info

Product

Resources

About